Novartis AG's revenue has grown 8.9% a year over three years, and grown 2.3% a year over five, with earnings per share compounding at 31%. Revenue growth, 3-year annual rate: +8.9% (Drug Manufacturers - General median +5.1%). Revenue growth, 5-year rate: +2.3%, growth has picked up over the last three years. Earnings per share, 3-year rate: +31%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 11, FY2015 to FY2025, as filed.

NVSNovartis AG

Healthcare

$151.11+19% 1Y

$151.11

$118.2052 weeks$163.64

Is it growing?

Good

Operating margin widening (+10.5 points). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

Margin direction+10.5 points operatingSEC EDGAR · Jun 30, 2025

Trailing-twelve-month operating margin, 34.9% now against 24.4% a year earlier.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NVS growing?

Novartis AG's revenue has grown 8.9% a year over three years, and grown 2.3% a year over five, with earnings per share compounding at 31%.

+8.9%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +5.1% · steady growth, ahead of inflation · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +2.3%
Revenue growth, 5-year rate · +8.9% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +31%
Earnings per share, 3-year rate · revenue +8.9% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed